Gotham Asset Management LLC Has $17.33 Million Stock Holdings in Natera, Inc. (NASDAQ:NTRA)

Gotham Asset Management LLC boosted its position in shares of Natera, Inc. (NASDAQ:NTRA) by 9.9% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 109,504 shares of the medical research company’s stock after purchasing an additional 9,895 shares during the period. Gotham Asset Management LLC owned 0.08% of Natera worth $17,334,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Smartleaf Asset Management LLC increased its stake in Natera by 50.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 657 shares of the medical research company’s stock valued at $104,000 after acquiring an additional 220 shares during the period. SeaBridge Investment Advisors LLC bought a new position in Natera in the fourth quarter worth $2,894,000. SYM FINANCIAL Corp acquired a new stake in Natera during the fourth quarter worth $256,000. KBC Group NV increased its holdings in Natera by 753.8% in the 4th quarter. KBC Group NV now owns 27,551 shares of the medical research company’s stock valued at $4,361,000 after buying an additional 24,324 shares during the period. Finally, Steward Partners Investment Advisory LLC raised its stake in shares of Natera by 1,328.0% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 357 shares of the medical research company’s stock valued at $57,000 after buying an additional 332 shares in the last quarter. Hedge funds and other institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NTRA opened at $150.99 on Friday. Natera, Inc. has a one year low of $92.14 and a one year high of $183.00. The business has a fifty day moving average of $147.51 and a 200 day moving average of $155.64. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market capitalization of $20.41 billion, a P/E ratio of -85.79 and a beta of 1.79.

Natera (NASDAQ:NTRA) last released its earnings results on Thursday, May 8th. The medical research company reported ($0.50) EPS for the quarter, topping analysts’ consensus estimates of ($0.59) by $0.09. The company had revenue of $501.83 million for the quarter, compared to analysts’ expectations of $446.68 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The firm’s revenue was up 36.5% compared to the same quarter last year. During the same quarter last year, the business earned ($0.56) EPS. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.49 EPS for the current year.

Insider Activity

In other Natera news, insider Solomon Moshkevich sold 6,000 shares of the business’s stock in a transaction that occurred on Wednesday, March 5th. The stock was sold at an average price of $143.29, for a total value of $859,740.00. Following the completion of the transaction, the insider now directly owns 143,768 shares of the company’s stock, valued at approximately $20,600,516.72. The trade was a 4.01 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Steven Leonard Chapman sold 87,272 shares of the company’s stock in a transaction dated Wednesday, March 5th. The stock was sold at an average price of $143.40, for a total transaction of $12,514,804.80. Following the completion of the transaction, the chief executive officer now owns 203,354 shares of the company’s stock, valued at approximately $29,160,963.60. This trade represents a 30.03 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 152,436 shares of company stock worth $22,019,079. 7.60% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

NTRA has been the subject of several recent analyst reports. Morgan Stanley increased their price objective on Natera from $176.00 to $185.00 and gave the stock an “overweight” rating in a research note on Wednesday, March 5th. Canaccord Genuity Group reissued a “buy” rating and set a $180.00 price target on shares of Natera in a report on Wednesday, February 26th. Royal Bank of Canada began coverage on shares of Natera in a research note on Thursday, March 13th. They set an “outperform” rating and a $251.00 price objective on the stock. StockNews.com upgraded shares of Natera from a “sell” rating to a “hold” rating in a research note on Friday. Finally, Barclays boosted their target price on Natera from $160.00 to $190.00 and gave the stock an “overweight” rating in a report on Friday. One analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $181.82.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.